Differences between oral medication and long-lasting effects

"Further study needed to find suitable patient population" The second new drug targeting EGFR mutations, which are rare in non-small cell lung cancer, has been released in Korea. Takeda Pharmaceutical's Exkivity is expected to compete with oral drugs and long reaction duration.

Takeda Pharmaceutical Korea held a press conference at The Plaza Hotel in Jung-gu, Seoul on the 1st and officially announced the launch of the new non-small cell lung cancer drug 'Exkivity'.

Exkivity is a targeted treatment for EGFR Exxon 20 inserted mutated non-small cell lung cancer and can be used as a secondary treatment in patients who ha